Kenneth King, OD
Optometrist · Fort Worth, TXNPI 1750469680
Payments from drug & device makers
Across 445 payments — averaging $87.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$23K
- Rxsight Inc$6K
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$1K
- Glaukos Corporation$1K
- Biotissue Holdings Inc.$924
- plus $5K from 21 others
What the payments were for
- Consulting fees$4,50012%
- Speaking & faculty fees$17,22644%
- Travel & lodging$3,1588%
- Food & beverage$14,19436%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 105 | $22,641 |
| Rxsight Inc | 42 | $6,198 |
| AbbVie(2 entities) | 64 | $1,880 |
| Sun Pharmaceutical Industries Inc. | 43 | $1,478 |
| Glaukos Corporation | 16 | $1,018 |
| Biotissue Holdings Inc. | 25 | $924 |
| Alcon | 23 | $778 |
| Tarsus Pharmaceuticals, Inc. | 15 | $551 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 20 | $485 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $427 |
| Kala Pharmaceuticals, Inc. | 13 | $362 |
| Lensar, Inc. | 4 | $317 |
| Harrow Eye, LLC | 12 | $302 |
| Novartis | 11 | $252 |
| Oyster Point Pharma, Inc. | 6 | $248 |
| Carl Zeiss Meditec USA, Inc. | 6 | $240 |
| Shire North American Group Inc | 6 | $222 |
| Dompe US, Inc. | 4 | $202 |
| Johnson & Johnson Vision Care, Inc. | 2 | $144 |
| Astellas Pharma US Inc | 1 | $107 |
| Aerie Pharmaceuticals, Inc. | 6 | $107 |
| Thea Pharma Inc. | 3 | $72 |
| Eyevance Pharmaceuticals LLC | 3 | $58 |
| Ocular Therapeutix, Inc. | 1 | $22 |
| Omeros Corporation | 1 | $20 |
| Optos, Inc. | 1 | $16 |
| Tearlab Corp | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$20,127
- XIIDRA$18,549
- RXSIGHT CONTACT LENS$4,618
- RXSIGHT INJECTOR CARTRIDGE$4,618
- RXSIGHT INJECTOR HANDPIECE$4,618
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$4,618
- LIGHT ADJUSTABLE LENS (LAL)$4,618
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$761
- CEQUA$588
- BLINK NUTRITEARS$400
- iDoseTR$285
- Tecnis IOL$247
- TRYPTYR$241
- VUITY$238
- DURYSTA$236
- EYSUVIS$222
- LENSAR LASER SYSTEM$174
- CIRRUS HD-OCT$134
- Oxervate$125
- Acuvue$120
How this compares
$39,078 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 66 | $85,139 |
| MieboPerfluorohexyloctane/Pf | 70 | $52,370 |
| RestasisCyclosporine | 40 | $46,513 |
| CequaCyclosporine | 34 | $32,640 |
| LumiganBimatoprost | 50 | $28,842 |
| XdemvyLotilaner | 14 | $27,468 |
| TyrvayaVarenicline Tartrate | 16 | $22,827 |
| VevyeCyclosporine | 28 | $20,658 |
| VyzultaLatanoprostene Bunod | 25 | $17,595 |
| RhopressaNetarsudil Mesylate | 29 | $14,698 |
| Cyclosporine | 15 | $12,881 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $7,277 |
| Lotemax SmLoteprednol Etabonate | 28 | $6,942 |
| Alphagan PBrimonidine Tartrate | 20 | $4,305 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $4,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $22,641 | $155,104161 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,880 | $86,938123 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,478 | $32,64034 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $551 | $27,46814 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $248 | $22,82716 claims |
| Harrow Eye, LLCVevye | $302 | $20,65828 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $107 | $14,69829 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $485 | $8,36839 claims |
| AlconSimbrinza | $778 | $4,16412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Fort Worth
- Xinnan WangFort Worth$125K
- Robert ChuFort Worth$59K
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Bryan FrazierTyler$1.4M
- Derek CunninghamAustin$940K
- Wendy ChungKaty$900K
- Phillip BrunsonHouston$766K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$568K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.